Walden Biosciences
PrivateLast Round
Series A
Oct 6, 2020
Total Funding Raised
$51M
Company Overview
Walden Biosciences is a biotechnology company that develops targeted therapies for kidney diseases, including chronic kidney disease and acute kidney injury.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Walden Biosciences Comparables
Compare Walden Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| River 3 Renal Corp. | 86% | |
| Purespring Therapeutics | 77% | |
| Dimerix Ltd | 76% |
Walden Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 6, 2020 |
Key People
Founding team and executive leadership
Walden Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCB Ventures | Series A |
| ARCH Venture Partners | Series A |
| UCB Ventures | Series A |
| ARCH Venture Partners | Series A |
| ATEM Capital | Series A |
| Pandect Bioventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 28, 2025
Howard Mayer, M.D. appointed to the Board of Directors.
Recent news
Latest coverage and updates
- attends_eventSep 8, 2026
Walden Biosciences, Inc. will attend event 24th Annual Morgan Stanley Global Healthcare Conference on Sep 14th '26.
Walden Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Walden Biosciences's valuation, stock price, and market status.
Is Walden a public or private company?
Walden is a private company.
What is the current stock price of Walden?
Walden is a private company with no public stock price. No recent secondary market data is available.
How much is Walden worth (valuation)?
Valuation information for Walden is not publicly available.
Can I buy Walden stock?
Walden shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Walden's last funding round?
Walden's most recent funding round was Series A on October 6, 2020.
Who are the main investors in Walden?
Key investors in Walden include UCB Ventures, UCB Ventures, ARCH Venture Partners.
Will Walden IPO soon?
No public IPO plans have been announced for Walden.
How can I track Walden secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Walden's secondary market activity and sign up for updates.